Professor Andrew Briggs

  • Chair in Health Economics (Health Economics and Health Technology Assessment)
  • Associate (School of Medicine, Dentistry and Nursing)

telephone: 01413305017
email: Andrew.Briggs@glasgow.ac.uk

Research interests

Andrew holds the William R Lindsay Chair in Health Economics at the University of Glasgow, having joined the University in 2005.  Previously, he held the position of Reader in Health Economics at the University of Oxford's Health Economics Research Centre (HERC). In addition, he spent the academic year 1999/2000 at the Centre for Evaluation of Medicines (CEM), at McMaster University and he remains a research associate of both CEM and HERC.

Andrew has expertise in all areas of health economic evaluation.  He has published well over 100 articles in the peer-reviewed literature.  He has particularly focused on statistical methods for cost-effectiveness analysis.  This includes statistical methods for estimation of parameters for cost-effectiveness models as well as statistical analysis of cost-effectiveness alongside clinical trials.  He also has a more general interest in epidemiological methods, in particular the use of prognostic scoring methods for predicting health outcomes and the relationship with heterogeneity in cost-effectiveness.

Andrew recently took a leadership role as co-chair of the Joint Society for Medical Decision Making (SMDM) and International Society for PharamacoEconomics and Outcomes Research (ISPOR) Task Force on Modelling Methods.  The Task Force, which was responsible for producing a set of seven papers covering all aspects of modelling methods applied to medical decision making and health technology assessment.  He is also the author of two successful textbooks, one published by OUP entitled Decision Modelling for Health Economic Evaluation, and another published by Wiley entitled Statistical Methods for Cost-Effectiveness Analysis.

In addition to his role at the University of Glasgow, he also serves as Editor of the journal Health Economics, and is on the editorial board of Value in Health.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • A
    A
    2017 - 2017
     

Supervision

Publications

List by: Type | Date

Jump to: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
Number of items: 199.

2017

Sullivan, F.M. et al. (2017) Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer, 17, 187. (doi:10.1186/s12885-017-3175-y) (PMID:28284200) (PMCID:PMC5346215)

Grieve, E., and Briggs, A. (2017) A Methodological Approach for Measuring the Impact of HTA. Technical Report. F1000Research.

Bousquet, J. et al. (2017) Erratum to: scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 7, 5. (doi:10.1186/s13601-016-0135-6) (PMID:28239450) (PMCID:PMC5319069)

Parker, C., Woods, B., Eaton, J., Ma, E., Selby, R., Benson, E., Engstrom, A., Sajosi, P., Briggs, A., and Bonthapally, V. (2017) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics, 20(1), pp. 8-18. (doi:10.1080/13696998.2016.1219358) (PMID:27472034)

2016

Bousquet, J. et al. (2016) ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 6, 47. (doi:10.1186/s13601-016-0137-4) (PMID:28050247) (PMCID:PMC5203711)

Briggs, A. (2016) A view from the bridge: health economic evaluation - a value-based framework? Health Economics, 25(12), pp. 1499-1502. (doi:10.1002/hec.3448) (PMID:27870333)

Wilkinson, T. et al. (2016) The international decision support initiative reference case for economic evaluation: an aid to thought. Value in Health, 19(8), pp. 921-928. (doi:10.1016/j.jval.2016.04.015) (PMID:27987641)

Gumley, A. et al. (2016) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). Schizophrenia Research, (doi:10.1016/j.schres.2016.11.026) (PMID:27894822) (In Press)

Briggs, A. H., Parfrey, P. S., Khan, N., Tseng, S., Dehmel, B., Kubo, Y., Chertow, G. M., and Belozeroff, V. (2016) Analyzing health-related quality of life in the evolve trial: the joint impact of treatment and clinical events. Medical Decision Making, 36(8), pp. 965-972. (doi:10.1177/0272989x16638312) (PMID:26987347) (Early Online Publication)

Wildman, J., McMeekin, P., Grieve, E., and Briggs, A. (2016) Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. Social Science and Medicine, 169, pp. 141-148. (doi:10.1016/j.socscimed.2016.09.033) (PMID:27721138)

Bouttell, J., Lewsey, J., Geue, C., Antony, G., Briggs, A., McCartney, G., Hutchinson, S., Graham, L., and Heydtmann, M. (2016) The SCottish alcoholic liver disease evaluation: a population-level matched cohort study of hospital-based costs, 1991-2011. PLoS ONE, 11(10), e0162980. (doi:10.1371/journal.pone.0162980) (PMID:27783619)

Willett, K. et al. (2016) Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a randomized clinical trial. JAMA: Journal of the American Medical Association, 316(14), pp. 1455-1463. (doi:10.1001/jama.2016.14719) (PMID:27727383)

Williams, C., Lewsey, J. D., Briggs, A. H., and Mackay, D. F. (2016) Estimation of survival probabilities for use in cost-effectiveness analysis: a comparison of a multi-state modelling survival analysis approach with partitioned survival and Markov decision-analytic modelling. Medical Decision Making, (doi:10.1177/0272989X16670617) (PMID:27698003) (Early Online Publication)

Keene, D. J. et al. (2016) The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. Health Technology Assessment, 20(75), (doi:10.3310/hta20750) (PMID:27735787)

Städler, N., Shang, A., Bosch, F., Briggs, A., Goede, V., Berthier, A., Renaudin, C., and Leblond, V. (2016) A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia. Advances in Therapy, 33(10), pp. 1814-1830. (doi:10.1007/s12325-016-0398-2) (PMID:27535291)

Hoogendoorn, M. et al. (2016) Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine? Value in Health, 19(6), pp. 800-810. (doi:10.1016/j.jval.2016.04.002) (PMID:27712708)

Wolowacz, S. E., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A., and Norman, R. (2016) Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health, 19(6), pp. 704-719. (doi:10.1016/j.jval.2016.06.001) (PMID:27712695)

Tabberer, M., Gonzalez-McQuire, S., Muellerova, H., Briggs, A., Rutten-van Molken, M., Chambers, M., and Lomas, D. A. (2016) Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Medical Decision Making, (doi:10.1177/0272989X16662009) (PMID:27486218) (Early Online Publication)

Bousquet, J. et al. (2016) Scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016(6), 29. (doi:10.1186/s13601-016-0116-9) (PMID:27478588) (PMCID:PMC4966705)

Lawson, K., Briggs, A., Lewsey, J., Ford, I., Watt, G., Tunstall-Pedoe, H., Woodward, M., Ritchie, L., Kent, S., and Neilson, M. (2016) A cardiovascular disease policy model: part 2 – preparing for economic evaluation and to assess health inequalities. Open Heart, 3(1), e000140. (doi:10.1136/openhrt-2014-000140) (PMID:27335653) (PMCID:PMC4908904)

Lee, M. M.Y. et al. (2016) Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 3(1), e000371. (doi:10.1136/openhrt-2015-000371) (PMID:27110377) (PMCID:PMC4838768)

Boyd, K. A., Briggs, A. H., Bauld, L., Sinclair, L., and Tappin, D. (2016) Are financial incentives cost-effective to support smoking cessation during pregnancy? Addiction, 111(2), pp. 360-370. (doi:10.1111/add.13160) (PMID:26370095)

Briggs, A., and Nugent, R. (2016) Editorial. Health Economics, 25(S1), pp. 6-8. (doi:10.1002/hec.3321) (PMID:26804358)

Thiele, H. et al. (2016) Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 172, pp. 160-169. (doi:10.1016/j.ahj.2015.11.006) (PMID:26856228)

Becker, U., Briggs, A. H., Moreno, S. G., Ray, J. A., Ngo, P., and Samanta, K. (2016) Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy. Value in Health, 19(4), pp. 374-382. (doi:10.1016/j.jval.2015.12.018) (PMID:27325329)

Tremblay, G., Livings, C., Crowe, L., Kapetanakis, V., and Briggs, A. (2016) Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. ClinicoEconomics and Outcomes Research, 2016(8), pp. 323-333. (doi:10.2147/CEOR.S107498) (PMID:27418847) (PMCID:PMC4934460)

Williams, C., Lewsey, J. D., Briggs, A. H., and Mackay, D. F. (2016) Cost-effectiveness analysis in R using a multi-state modelling survival analysis framework: a tutorial. Medical Decision Making, (doi:10.1177/0272989X16651869) (PMID:27281337) (Early Online Publication)

2015

Jahoda, A., Melville, C., Cooper, S.-A., Hastings, R., Briggs, A., Dagnan, D., Hatton, C., McConnachie, A., Williams, C., and Jones, R. P. (2015) BEAT-IT: a randomised controlled trial comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: summary of study protocol. Trials, 16, 595. (doi:10.1186/s13063-015-1103-5) (PMID:26714891) (PMCID:PMC4696180)

Belozeroff, V., Chertow, G. M., Graham, C. N., Dehmel, B., Parfrey, P. S., and Briggs, A. H. (2015) Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value in Health, 18(8), pp. 1079-1087. (doi:10.1016/j.jval.2015.08.007) (PMID:26686794)

Nam, J. et al. (2015) Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015(13), 19. (doi:10.1186/s12962-015-0045-9) (PMID:26578850) (PMCID:PMC4647286)

McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi:10.1016/j.jval.2015.09.887) (PMID:26532224)

Bousquet, J. et al. (2015) MACVIA-ARIA sentinel networK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy, 70(11), pp. 1372-1392. (doi:10.1111/all.12686) (PMID:26148220)

Reed, S. D. et al. (2015) Tools for economic analysis of patient management interventions in heart failure cost-effectiveness model: a web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. American Heart Journal, 170(5), pp. 951-960. (doi:10.1016/j.ahj.2015.08.015) (PMID:26542504)

Boyd, K. A., Jones, R. J., Paul, J., Birrell, F., Briggs, A. H., and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi:10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Lorgelly, P. K., Lorimer, K., Fenwick, E. A.L., Briggs, A. H., and Anand, P. (2015) Operationalising the capability approach as an outcome measure in public health: the development of the OCAP-18. Social Science and Medicine, 142, pp. 68-81. (doi:10.1016/j.socscimed.2015.08.002) (PMID:26291444)

Gumley, A. et al. (2015) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). Psychosis, pp. 1-13. (doi:10.1080/17522439.2015.1100669)

Old, O., Moayyedi, P., Love, S., Roberts, C., Hapeshi, J., Foy, C., Stokes, C., Briggs, A., Jankowski, J., and Barr, H. (2015) Barrett's oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. Journal of Medical Screening, 22(3), pp. 158-164. (doi:10.1177/0969141315575052) (PMID:25767103)

Wolowacz, S., Pearson, I., Shannon, P., Chubb, B., Gundgaard, J., Davies, M., and Briggs, A. (2015) Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabetic Medicine, 32(8), pp. 1023-1035. (doi:10.1111/dme.12663) (PMID:25484028)

Govan, L., Wu, O., Lindsay, R., and Briggs, A. (2015) How do diabetes models measure up? A review of diabetes economic models and ADA guidelines. Journal of Health Economics and Outcomes Research, 3(2), pp. 132-152.

Husereau, D., Drummond, M., Petrou, S., Greenberg, D., Mauskopf, J., Augustovski, F., Briggs, A. H., Moher, D., Loder, E., and Carswell, C. (2015) Reply to Roberts et al.: CHEERS is sufficient for reporting cost-benefit analysis, but may require further elaboration. PharmacoEconomics, 33(5), pp. 535-536. (doi:10.1007/s40273-015-0277-8) (PMID:25893576)

Stollenwerk, B., Lhachimi, S. K., Briggs, A., Fenwick, E., Caro, J. J., Siebert, U., Danner, M., and Gerber-Grote, A. (2015) Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Economics, 24(4), pp. 481-490. (doi:10.1002/hec.3041) (PMID:24590819)

Geue, C., Lorgelly, P., Lewsey, J., Hart, C., and Briggs, A. (2015) Hospital expenditure at the end-of-life: what are the impacts of health status and health risks? PLoS ONE, 10(3), e0119035. (doi:10.1371/journal.pone.0119035) (PMID:25746728) (PMCID:PMC4352086)

Layland, J. et al. (2015) Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 36(2), pp. 100-111. (doi:10.1093/eurheartj/ehu338) (PMID:25179764) (PMCID:PMC4291317)

Cook, J. A. et al. (2015) Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. Trials, 16(1), 12. (doi:10.1186/s13063-014-0526-8) (PMID:25928502) (PMCID:PMC4302137)

Devereux, G. et al. (2015) Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 16, 267. (doi:10.1186/s13063-015-0782-2) (PMID:26058585) (PMCID:PMC4465017)

Haines, P., Tremblay, G., and Briggs, A. (2015) A criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data. Journal of Health Economics and Outcomes Research, 2(2), pp. 147-160.

Lewsey, J. et al. (2015) Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 15(3), (doi:10.1186/s12883-014-0257-1) (PMID:25591718) (PMCID:PMC4320501)

Logue, J. et al. (2015) SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. BMJ Open, 5(5), e008106. (doi:10.1136/bmjopen-2015-008106) (PMID:26002692) (PMCID:PMC4442215)

2014

Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi:10.1007/s00125-014-3383-9)

Geue, C., Briggs, A., Lewsey, J., and Lorgelly, P. (2014) Population ageing and healthcare expenditure projections: new evidence from a time to death approach. European Journal of Health Economics, 15(5), pp. 885-896. (doi:10.1007/s10198-013-0543-7)

Boyd, K.A., Briggs, A.H., Bauld, L., Sinclair, L., and Tappin, D. (2014) Are financial incentives cost-effective for smoking cessation amongst pregnant women? European Journal of Public Health, 24(S2), p. 146. (doi:10.1093/eurpub/cku162.090)

Bousquet, J. et al. (2014) Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 44(2), pp. 304-323. (doi:10.1183/09031936.00014614)

Hoogendoorn, M. et al. (2014) Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value in Health, 17(5), pp. 525-536. (doi:10.1016/j.jval.2014.03.1721)

Cook, J. A., Hislop, J. M., Altman, D. G., Briggs, A. H., Fayers, P. M., Norrie, J. D., Ramsay, C. R., Harvey, I. M., and Vale, L. D. (2014) Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice. Clinical Trials, 11(3), pp. 300-308. (doi:10.1177/1740774514521907) (PMID:24603006)

Boyd, K.A., Jones, R.J., Paul, J., Briggs, A., and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi:10.1002/bjs.9510)

Cooke, J. A. et al. (2014) Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. Health Technology Assessment, 18(28), v-vi, 1. (doi:10.3310/hta18280)

Levy, A. R., Briggs, A. H., Johnston, K., MacLean, J. R., Yuan, Y., L’Italien, G. J., Kalsekar, A., and Schnitzler, M. A. (2014) Projecting long-term graft and patient survival after transplantation. Value in Health, 17(2), pp. 254-260. (doi:10.1016/j.jval.2014.01.001)

Caro, J.J., Eddy, D. M., Kan, H., Kaltz, C., Patel, B., Eldessouki, R., and Briggs, A. H. (2014) Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value in Health, 17(2), pp. 174-182. (doi:10.1016/j.jval.2014.01.003)

Looker, H.C. et al. (2014) Risk stratification for diabetic eye screening: reply to Stratton I. M. and Aldington S. J. Diabetologia, 57(1), pp. 260-261. (doi:10.1007/s00125-013-3099-2)

Samyshkin, Y., Kotchie, R. W., Mörk, A.-C., Briggs, A. H., and Bateman, E. D. (2014) Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. European Journal of Health Economics, 15(1), pp. 69-82. (doi:10.1007/s10198-013-0456-5) (PMID:23392624) (PMCID:PMC3889819)

Briggs, A. (2014) Statistical issues in economic evaluations. In: Culyer, A. J. (ed.) Encyclopedia of Health Economics. Elsevier, pp. 352-361. ISBN 9780123756787 (doi:10.1016/B978-0-12-375678-7.01418-8)

Campbell, J. D., McQueen, R. B., and Briggs, A. (2014) The “E” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Annals of the American Thoracic Society, 11(Sup 2), S105-S111. (doi:10.1513/AnnalsATS.201309-295RM)

Dundas, R., Ouédraogo, S., Bond, L., Briggs, A.H., Chalmers, J., Gray, R., Wood, R., and Leyland, A.H. (2014) Evaluation of Health in Pregnancy grants in Scotland: a protocol for a natural experiment. BMJ Open, 4(10), e006547. (doi:10.1136/bmjopen-2014-006547)

Hislop, J. et al. (2014) Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) Systematic Review. PLoS Medicine, 11(5), e1001645. (doi:10.1371/journal.pmed.1001645)

Lewsey, J.D. et al. (2014) A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. Heart, 101(3), pp. 201-208. (doi:10.1136/heartjnl-2014-305637)

Munge, K., and Briggs, A. H. (2014) The progressivity of health-care financing in Kenya. Health Policy and Planning, 29(7), pp. 912-920. (doi:10.1093/heapol/czt073)

Willett, K. et al. (2014) Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing close contact casting (CCC) to open surgical reduction and internal fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. BMC Musculoskeletal Disorders, 15, 79. (doi:10.1186/1471-2474-15-79) (PMID:24621174) (PMCID:PMC4234276)

2013

Berry, C. et al. (2013) Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. American Heart Journal, 166(4), 662-668.e3. (doi:10.1016/j.ahj.2013.07.011)

Jaime Caro, J., Eddy, D.M., Hollingworth, W., Tsevat, J., McDonald, K.M., Wong, J.B., Briggs, A.H., Siebert, U., and Kuntz, K.M. (2013) ISPOR-SMDM task force’s recommendations for good modeling practices—reply to letter to the editor by Corro Ramos. Value in Health, 16(6), p. 1108. (doi:10.1016/j.jval.2013.06.016)

Looker, H.C. et al. (2013) Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia, 56(8), pp. 1716-1725. (doi:10.1007/s00125-013-2928-7)

Roberts, N.J., Lewsey, J.D., Gillies, M., Briggs, A.H., Belozeroff, V., Globe, D.R., Chiou, C.-F., Lin, S.-L., and Globe, G. (2013) Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: a retrospective cohort study from 1981-2009. Respiratory Medicine, 107(8), pp. 1172-1177. (doi:10.1016/j.rmed.2013.04.004)

Tigbe, W.W., Briggs, A.H., and Lean, M.E.J. (2013) A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. International Journal of Obesity, 37(8), pp. 1135-1139. (doi:10.1038/ijo.2012.186)

Garrison, L.P., Towse, A., Briggs, A., de Pouvourville, G., Grueger, J., Mohr, P.E., Severens, J.L., Siviero, P., and Sleeper, M. (2013) Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ispor good practices for performance-based risk-sharing arrangements task force. Value in Health, 16(5), pp. 703-719. (doi:10.1016/j.jval.2013.04.011)

Hemingway, H. et al. (2013) Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. British Medical Journal, 2013(346), e5595. (doi:10.1136/bmj.e5595)

Riley, R. D. et al. (2013) Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Medicine, 10(2), e1001380. (doi:10.1371/journal.pmed.1001380)

Murphy, A., Fenwick, E., Toff, W.D., Neilson, M.P., Berry, C., Uren, N., Oldroyd, K.G., and Briggs, A.H. (2013) Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. International Journal of Technology Assessment in Health Care, 29(01), pp. 12-19. (doi:10.1017/S0266462312000670)

Boyd, K., and Briggs, A. (2013) Statistical issues with trial data and economic modeling for cost-effectiveness evaluation. In: Tang, W. and Tu, X. (eds.) Modern Clinical Trial Analysis. Series: Applied bioinformatics and biostatistics in cancer research. Springer-Verlag: New York, NY, USA, pp. 149-166. ISBN 9781461443216 (doi:10.1007/978-1-4614-4322-3_6)

Davies, C., Briggs, A., Lorgelly, P., Garellick, G., and Malchau, H. (2013) The 'hazards' of extrapolating survival curves. Medical Decision Making, 33(3), pp. 369-380. (doi:10.1177/0272989X12475091) (PMID:23457025)

Grutters, J.P.C., Sculpher, M., Briggs, A.H., Severens, J.L., Candel, M.J., Stahl, J.E., de Ruysscher, D., Boer, A., Ramaekers, B.L.T., and Joore, M.A. (2013) Acknowledging patient heterogeneity in economic evaluation. PharmacoEconomics, 31(2), pp. 111-123. (doi:10.1007/s40273-012-0015-4)

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., and Loder, E. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 16(2), pp. 231-250. (doi:10.1016/j.jval.2013.02.002)

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., and Loder, E. (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. British Medical Journal, 346(f1049), (doi:10.1136/bmj.f1049)

Lloyd, S.M. et al. (2013) Long-term effects of statin treatment in elderly people: Extended follow-up of the PROspective study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE, 8(9), e72642. (doi:10.1371/journal.pone.0072642)

Silveirinha de Oliveira, E., Aspinall, P., Briggs, A., Cummins, S., Leyland, A., Mitchell, R., Roe, J., and Ward Thompson, C. (2013) How effective is the Forestry Commission Scotland's woodland improvement programme--'Woods In and Around Towns' (WIAT)--at improving psychological well-being in deprived urban communities? A quasi-experimental study. BMJ Open, 3(8), e003648. (doi:10.1136/bmjopen-2013-003648)

2012

Geue, C., Lewsey, J., Lorgelly, P., Govan, L., Hart, C., and Briggs, A. (2012) Spoilt for choice: implications of costing hospital episode statistics. Health Economics, 21(10), pp. 1201-1216. (doi:10.1002/hec.1785)

Briggs, A.H., Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J., and Paltiel, A.D. (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value in Health, 15(6), pp. 835-842. (doi:10.1016/j.jval.2012.04.014)

Caro, J.J., Briggs, A.H., Siebert, U., and Kuntz, K.M. (2012) modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value in Health, 15(6), pp. 796-803. (doi:10.1016/j.jval.2012.06.012)

Wu, O., Briggs, A., and MacIntyre, K. (2012) Mobile phone use for contacting emergency services in life-threatening circumstances. Journal of Emergency Medicine, 42(3), pp. 291-298. (doi:10.1016/j.jemermed.2011.02.022)

Briggs, A. (2012) The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Research in Medicine, 3(1), e25-e26. (doi:10.1016/j.ehrm.2012.01.001)

Briggs, A.H., Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J., and Paltiel, A.D. (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group - 6. Medical Decision Making, 32(5), pp. 722-732. (doi:10.1177/0272989X12458348)

Caro, J.J., Briggs, A.H., Siebert, U., and Kuntz, K.M. (2012) Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force - 1. Medical Decision Making, 32(5), pp. 667-677. (doi:10.1177/0272989X12454577)

Govan, L. et al. (2012) The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. Diabetologia, 55(9), pp. 2356-2360. (doi:10.1007/s00125-012-2601-6)

Roberts, N.J., Boyd, K., Briggs, A.H., Caress, A.L., and Partridge, M.R. (2012) Nurse led versus lay educators support for those with asthma in primary care: a costing study. BMC Pulmonary Medicine, 12(52), (doi:10.1186/1471-2466-12-52)

Tappin, D.M. et al. (2012) The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. Trials, 13(113), (doi:10.1186/1745-6215-13-113) (PMID:22818493) (PMCID:PMC3482147)

2011

McLean, R.C., Briggs, A.H., Slack, R., Zamvar, V., Berg, G.A., El-Shafei, H., Oldroyd, K.G., and Pell, J.P. (2011) Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. European Journal of Cardio-Thoracic Surgery, 40(6), pp. 1508-1514. (doi:10.1016/j.ejcts.2011.01.088)

Boyd, K.A., Briggs, A.H., Fenwick, E., Norrie, J., and Stock, S. (2011) Power and sample size for cost-effectiveness analysis: fFN neonatal screening. Contemporary Clinical Trials, 32(6), pp. 893-901. (doi:10.1016/j.cct.2011.07.007)

Govan, L. et al. (2011) Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 34(9), pp. 1992-1997. (doi:10.2337/dc10-2099)

Macpherson, K.J. et al. (2011) Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 11(1), p. 38. (doi:10.1186/1471-2377-11-38)

Price, M.J., Welton, N.J., Briggs, A.H., and Ades, A.E. (2011) Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. Value in Health, 14(2), pp. 205-218. (doi:10.1016/j.jval.2010.08.001)

Starkie, H.J., Briggs, A.H., Chambers, M.G., and Jones, P. (2011) Predicting EQ-5D Values Using the SGRQ. Value in Health, 14(2), pp. 354-360. (doi:10.1016/j.jval.2010.09.011)

Bauld, L., Boyd, K. A., Briggs, A. H., Chesterman, J., Ferguson, J., Judge, K., and Hiscock, R. (2011) One-Year Outcomes and a Cost-Effectiveness Analysis for Smokers Accessing Group-Based and Pharmacy-Led Cessation Services. Nicotine and Tobacco Research, 13(2), pp. 135-145. (doi:10.1093/ntr/ntq222)

Barton, P., Andronis, L., Briggs, A., McPherson, K., and Capewell, S. (2011) Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal, 343, d4044. (doi:10.1136/bmj.d4044)

Bousquet, J. et al. (2011) How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. Allergy, 66(6), pp. 765-774. (doi:10.1111/j.1398-9995.2011.02590.x)

Boyd, K.A., Briggs, A., Paul, J., Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L., and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi:10.1186/1745-6215-12-S1-A41)

Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A., and Fenwick, E.L. (2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 14(1), pp. 15-23. (doi:10.1016/j.jval.2010.10.016)

Govan, L. et al. (2011) Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 54(8), pp. 2000-2008. (doi:10.1007/s00125-011-2176-7)

2010

Boyd, K.A., Fenwick, E., and Briggs, A. (2010) Using an iterative approach to economic evaluation in the drug development process. Drug Development Research, 71(8), pp. 470-477. (doi:10.1002/ddr.20421)

Mihaylova, B., Briggs, A., O'Hagan, A., and Thompson, S.G. (2010) Review of statistical methods for analysing healthcare resources and costs. Health Economics, 20(8), pp. 897-916. (doi:10.1002/hec.1653)

Briggs, A.H., Glick, H.A., Lozano-Ortega, G., Spencer, M., Calverley, P.M.A., Jones, P.W., and Vestbo, J. (2010) Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal, 35(3), pp. 532-539. (doi:10.1183/09031936.00153108)

Briggs, A., Ritchie, K., Fenwick, E., Chalkidou, K., and Littlejohns, P. (2010) Access with evidence development in the UK past experience, current initiatives and future potential. PharmacoEconomics, 28(2), pp. 163-170. (doi:10.2165/11531410-000000000-00000)

Lorgelly, P.K. et al. (2010) An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 12(1), pp. 66-74. (doi:10.1093/eurjhf/hfp172)

Briggs, A.H. (2010) Transportability of comparative effectiveness and cost-effectiveness between countries. Value in Health, 13, S22-S25. (doi:10.1111/j.1524-4733.2010.00751.x)

Campbell, H.E., Gray, A.M., Harris, A.L., Briggs, A.H., and Taylor, M.A. (2010) Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. British Journal of Cancer, 103(6), pp. 776-786. (doi:10.1038/sj.bjc.6605863)

Crott, R., and Briggs, A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. European Journal of Health Economics, 11(4), pp. 427-434. (doi:10.1007/s10198-010-0233-7)

Dolan, G.P., Stone, D.H., and Briggs, A. (2010) A systematic review of continuous performance task research in children prenatally exposed to alcohol. Alcohol and Alcoholism, 45(1), pp. 30-38. (doi:10.1093/alcalc/agp062)

Hollingworth, W., Campbell, J.D., Kowalski, J., Ravelo, A., Girod, I., Briggs, A., and Sullivan, S.D. (2010) Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Quality of Life Research, 19(3), pp. 323-331. (doi:10.1007/s11136-010-9590-z)

Johnston, K.M., Levy, A.R., Lima, V.D., Hogg, R.S., Tyndall, M.W., Gustafson, P., Briggs, A.H., and Montaner, J.S. (2010) Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS, 24(12), pp. 1929-1935. (doi:10.1097/QAD.0b013e32833af85d)

Langhorne, P. et al. (2010) Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), pp. 1301-1305. (doi:10.1136/jnnp.2009.195131)

Lewsey, J. et al. (2010) Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 8, p. 23. (doi:10.1186/1741-7015-8-23)

Lorgelly, P.K., Lawson, K.D., Fenwick, E.A.L., and Briggs, A.H. (2010) Outcome Measurement in Economic Evaluations of Public Health Interventions: a Role for the Capability Approach? International Journal of Environmental Research and Public Health, 7(5), pp. 2274-2289. (doi:10.3390/ijerph7052274)

2009

Levy, A., Harrigan, B., Johnston, K., and Briggs, A. (2009) Comparative effectiveness research through the looking glass. Medical Decision Making, 29(6), NP6-NP8. (doi:10.1177/0272989X09351590)

Lewsey, J. et al. (2009) Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2(5), pp. 475-483. (doi:10.1161/CIRCOUTCOMES.108.825968)

Jacobs-van der Bruggen, M. A. M., van Baal, P. H., Hoogenveen, R. T., Feenstra, T. L., Briggs, A. H., Lawson, K., Feskens, E. J. M., and Baan, C. A. (2009) Cost-effectiveness of lifestyle modification in diabetes patients. Diabetes Care, 32(8), pp. 1453-1458. (doi:10.2337/dc09-0363)

Wu, O., Levy, A.R., Briggs, A., Lewis, G., and Jardine, A. (2009) Acute rejection and chronic nephropathy: a systematic review of the literature. Transplantation, 87(9), pp. 1330-1339. (doi:10.1097/TP.0b013e3181a236e0)

Lewsey, J.D. et al. (2009) Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke, 40(4), pp. 1038-1043. (doi:10.1161/STROKEAHA.108.542787)

Mihaylova, B., Briggs, A., Hlatky, M., Armitage, J., Parish, S., Gray, A., and Collins, R. (2009) Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation: Cardiovascular Quality and Outcomes, 2(2), pp. 65-72. (doi:10.1161/CIRCOUTCOMES.108.808469)

Boyd, K.A., and Briggs, A.H. (2009) Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction, 104(2), pp. 317-325. (doi:10.1111/j.1360-0443.2008.02449.x)

Briggs, A., Starkie, H., and Wu, O. (2009) Health economics in asthma and COPD. In: Barnes, P.J., Drazen, J.M., Rennard, S.I. and Thomson, N.C. (eds.) Asthma and COPD. Academic Press/Elsevier: London, pp. 751-760. ISBN 9780123740014

Levy, A.R., Szabo, S., Briggs, A., Pleil, A., Davie, A., Zlateva, G., and Javitt, J. (2009) Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. Journal of Ophthalmology, 2009, 540431. (doi:10.1155/2009/540431) (PMID:20339464) (PMCID:PMC2836847)

2008

Barton, G.R., Briggs, A.H., and Fenwick, E.A.L. (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value in Health, 11(5), pp. 886-897. (doi:10.1111/j.1524-4733.2008.00358.x)

Hirst, A., Dutton, S., Wu, O., Briggs, A., Edwards, C., Waldenmaier, L., Maresh, M., Nicholson, A., and McPherson, K. (2008) A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids: the HOPEFUL study. Health Technology Assessment, 12(5),

Briggs, A.H., Spencer, M., Wang, H., Mannino, D., and Sin, D.D. (2008) Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Archives of Internal Medicine, 168(1), pp. 71-79. (doi:10.1001/archinternmed.2007.37)

Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., and Mukherjee, J. (2008) Impact of schizophrenia and schizophrenia treatment related adverse events on quality of life: direct utility elicitation. Health and Quality of Life Outcomes, 6(105), pp. 1-9. (doi:10.1186/1477-7525-6-105)

Claxton, K., Briggs, A.H., Buxton, M.J., Culyer, A.J., McCabe, C., Walker, S., and Sculpher, M.J. (2008) Value based pricing for NHS drugs: an opportunity not to be missed? British Medical Journal, 336(7638), pp. 251-254. (doi:10.1136/bmj.39434.500185.25)

Eckerman, S., Briggs, A., and Willan, A.R. (2008) Health technology assessment in the cost-disutility plane. Medical Decision Making, 28(2), pp. 172-181. (doi:10.1177/0272989X07312474)

Hirst, A., Dutton, S., Wu, O., Briggs, A., Edwards, C., Waldenmaier, L., Maresh, M., Nicholson, A., and McPherson, K. (2008) The HOPEFUL Study: a multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation (UAE) for the treatment of symptomatic uterine fibroids. Health Technology Assessment, 123(5), pp. 1-248.

Levy, A.R., Kowdley, K., Iloeje, U.H., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N., and Briggs, A.H. (2008) The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health, 11(3), pp. 527-538. (doi:10.1111/j.1524-4733.2007.00297.x)

Starkie, H., Briggs, A.H., and Chamber, M.G. (2008) Pharmacoeconomics in COPD: lessons for the future. International Journal of COPD, 3(1), pp. 71-88.

2007

Campbell, H., Briggs, A.H., Buxton, M., Kim, L., and Thompson, S. (2007) The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. Journal of Health Services Research and Policy, 12(1), pp. 11-17. (doi:10.1258/135581907779497594)

Briggs, A. et al. (2007) Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 93(9), pp. 1081-1086.

Culyer, A., McCabe, C., Briggs, A.H., Claxton, K., Buxton, M., Akehurst, R., Sculpher, M.J., and Brazier, J. (2007) Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 12(1), pp. 56-58.

Kim, L., Thompson, S., Briggs, A., Buxton, M., and Campbell, H. (2007) How cost-effective is screening for abdominal aortic aneurysms? Journal of Medical Screening, 14(1), pp. 46-52.

Luc, G., Ades, A., Sutton, A., Cooper, N., BriggS, A., and Caldwell, D. (2007) Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine, 26, pp. 3681-3699. (doi:10.1002/sim.2831)

Ossa, D.F., Briggs, A.H., McIntosh, E., Cowell, W., Littlewood, T., and Sculpher, M.J. (2007) Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. PharmacoEconomics, 25(3), pp. 223-237.

2006

Mihaylova, B., Briggs, A.H., Armitage, J., Parish, S., Gray, A., and Collins, R. (2006) Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. British Medical Journal, 333(7579), p. 1145. (doi:10.1136/bmj.38993.731725.BE)

Paul, J., Briggs, A., Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A., and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.

Briggs, A.H., Bousquet, J., Wallace, M., Busse, W.W., Clark, T.J.H., Pedersen, S.E., and Baternan, E.D. (2006) Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy, 61(5), pp. 531-536. (doi:10.1111/j.1398-9995.2006.01038.x)

Briggs, A.H., and Levy, A.R. (2006) Pharmacoeconomics and pharmacoepidemiology - Curious bedfellows or a match made in heaven? PharmacoEconomics, 24, pp. 1079-1086.

Briggs, A.H., Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D., and Burge, S. (2006) Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health, 9(4), pp. 227-235. (doi:10.1111/j.1524-4733.2006.00106.x)

Deckers, J., Goedhart, D., Boersma, E., Briggs, A., Bertrand, M., Ferrari, R., Remme, W., Fox, K., and imoons, M. (2006) Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal, 27, pp. 796-801. (doi:10.1093/eurheartj/ehi809)

Williams, C. et al. (2006) Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment, 10, 1-+.

2005

Manca, A., Rice, N., Sculpher, M.J., and Briggs, A.H. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics, 14(5), pp. 471-485. (doi:10.1002/hec.914)

Claxton, K., Sculpher, M., McCabe, C., Briggs, A.H., Akehurst, R., Buxton, M., Brazier, J., and O'Hagan, T. (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics, 14(4), pp. 339-347. (doi:10.1002/hec.985)

Briggs, A.H. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2. (doi:10.1111/j.1524-4733.2005.08101.x)

Briggs, A.H., Nixon, R., Dixon, S., and Thompson, S. (2005) Parametric modelling of cost data: some simulation evidence. Health Economics, 14(4), pp. 421-428. (doi:10.1002/hec.941)

Briggs, A. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2.

Clarke, P., Gray, A., Briggs, A., Stevens, R., Matthews, D., and Holman, R. (2005) Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia, 48(5), pp. 868-877.

Gagnon, Y., Levy, A., Spencer, M., Hurley, J., Frost, F., Mapel, D., and Briggs, A. (2005) Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respiratory Medicine, 99(12), pp. 1534-1545.

Manca, A., Rice, N., Sculpher, M., and Briggs, A. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.[erratum appears in Health Econ. Health Economics, 14(5), pp. 471-485.

Mihaylova, B., Briggs, A., Armitage, J., Parish, S., Gary, A., and Collins, R. (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet, 365(9473), pp. 1779-1785.

O'Hagan, T. et al. (2005) Incorporation of uncertainty in health economic modelling studies. PharmacoEconomics, 23(6), pp. 529-536.

Ramsey, S. et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value in Health, 8(5), pp. 521-533.

Reed, S. et al. (2005) Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. American Heart Journal, 149(3), pp. 434-443.

Spencer, M.D., Briggs, A.H., Grossman, R.J., and Rance, L. (2005) Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. PharmacoEconomics, 23(6), pp. 619-637.

2004

Clarke, P.M., Gray, A.M., Briggs, A., Farmer, A.J., Fenn, P.,, Stevenson, R.J., Matthews, D.R., Stratton, I.M., and Holman, R.R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47(10), pp. 1747-1759. (doi:10.1007/s00125-004-1527-z)

Briggs, A.H. (2004) Statistical approaches to handling uncertainty in health economic evaluation. Psychiatrist, 16(6), pp. 551-561.

Briggs, A. (2004) Statistical approaches to handling uncertainty in health economic evaluation. [29 refs]. European Journal of Gastroenterology and Hepatology, 16(6), pp. 551-561.

Briggs, A., Sculpher, M., Dawson, J., Fitzpatrick, R., Murray, D., and Malchau, H. (2004) The Use of Probabilistic Decision Models in Technology Assessment: The Case of Total Hip Replacement. Applied Health Economics and Health Policy, 3(2), pp. 78-79.

Clarke, P., Gray, A., Briggs, A., Farmer, A., Fenn, P., Stevens, R., Matthews, D., Stratton, I., and Holman, R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47, pp. 1747-1759. (doi:10.1007/s00125-004-1527-z)

Gagnon, Y., Levy, A., Iloeje, U., and Briggs, A. (2004) Treatment costs in Canada of health conditions resulting from chronic Hepatitis B infection. Journal of Clinical Gastroenterology, 38(Suppl), S179-S186.

Willan, A., Briggs, A., and Hoch, J. (2004) Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics, 13(5), pp. 461-475.

2003

Clarke, P., Gray, A., Legood, R., Briggs, A., and Holman, R. (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine, 20(6), pp. 442-450. (doi:10.1046/j.1464-5491.2003.00972.x)

Reed, S.D., Dillingham, P.W., Briggs, A.H., Veestra, D.L., and Sullivan, S.D. (2003) A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. Medical Decision Making, 23(3), pp. 252-264. (doi:10.1177/0272989X03023003007)

Briggs, A., Ades, A., and Price, M. (2003) Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making, 23(4), pp. 341-350.

Briggs, A., Clark, T., Wolstenholme, J., and Clark, P. (2003) Missing ... presumed at random: cost analysis of incomplete data. Health Economics, 12(5), pp. 377-393.

Craig, D. et al. (2003) New BMJ policy on economic evaluations. Economic evaluations should be judged on economic merit. British Medical Journal, 326(7386), p. 445.

Hoch, J., Briggs, A., and Willan, A. (2003) Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics, 11(5), pp. 415-430.

Hope, A., and Briggs, A. (2003) Concerns regarding the ISPOR Code of Ethics for Researchers. Value in Health, 7(4), pp. 510-511.

Tytgat, G., Heading, R., Muller-Lissner, S., Kamm, M., Scholmerich, J., Berstad, A., Fried, M., Chaussade, S., Jewell, D., and Briggs, A. (2003) Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Alimentary Pharmacology and Therapeutics, 18(3), pp. 291-301. (doi:10.1046/j.1365-2036.2003.01679.x)

2002

Briggs, A., Clark, T., Wolstenholme, J., and Clarke, P. (2002) Missing.... presumed at random: cost-analysis of incomplete data. Health Economics, 12(5), pp. 377-392. (doi:10.1002/hec.766)

O'Brien, B.J., and Briggs, A.H. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468. (doi:10.1191/0962280202sm304ra)

Briggs, A.H., O'Brien, B.J., and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401. (doi:10.1146/annurev.publhealth.23.100901.140534)

Blackhouse, G., Briggs, A., and O'Brien, B.J. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177. (doi:10.1177/02729890222063053)

Blackhouse, G., Briggs, A., and O'Brien, B. (2002) Estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22, pp. 170-174.

Blackhouse, G., Briggs, A., and O'Brien, B. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177.

Briggs, A.H., Goeree, R., Blackhouse, G., and O'Brien, B.J. (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308. (doi:10.1177/027298902400448867)

Briggs, A., Goeree, R., and O'Brien, B. (2002) Probabilistic analysis of models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308.

Briggs, A., O'Brien, B., and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401.

Goeree, R., O'Brien, B., Blackhouse, G., Marshall, J., Briggs, A., and Lad, R. (2002) Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value in Health, 5(4), pp. 312-328.

O'Brien, B., and Briggs, A. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468.

Price, M.J., and Briggs, A.H. (2002) Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics, 20(3), pp. 183-194.

2001

Sendi, P.P., and Briggs, A.H. (2001) Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Economics, 10(7), pp. 675-680. (doi:10.1002/hec.639)

Briggs, A.H., and O'Brien, B.J. (2001) The death of cost-minimization analysis? Health Economics, 10(2), pp. 179-184. (doi:10.1002/hec.584)

Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.

Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.

Briggs, A., and O'Brien, B. (2001) The death of cost-minimization analysis?. [23 refs]. Health Economics, 10(2), pp. 179-184.

Briggs, A., and Tambour, M. (2001) The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions. Drug Information Journal, 35(4), pp. 1455-1468.

Delaney, B.C., Wilson, S.L., Roalfe, A., Briggs, A.H., and Hobbs, F.D.R. (2001) Empirical treatment or prompt endoscopy? - author's reply. Lancet, 357, p. 1366. (doi:10.1016/S0140-6736(00)04492-5)

Glick, H., and Briggs, A. (2001) Cost-effectiveness of health care interventions: a guide to quantifying stochastic uncertainty and presenting the result of cost-effectiveness analyses. Expert Reviews in Pharmacoeconomics and Outcomes Research, 1(1), pp. 25-36.

Levy, A., Briggs, A., Demers, C., and O'Brien, B. (2001) Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. American Heart Journal, 142(3), pp. 537-543.

This list was generated on Thu Mar 30 21:14:39 2017 BST.
Number of items: 199.

Articles

Sullivan, F.M. et al. (2017) Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer, 17, 187. (doi:10.1186/s12885-017-3175-y) (PMID:28284200) (PMCID:PMC5346215)

Bousquet, J. et al. (2017) Erratum to: scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 7, 5. (doi:10.1186/s13601-016-0135-6) (PMID:28239450) (PMCID:PMC5319069)

Parker, C., Woods, B., Eaton, J., Ma, E., Selby, R., Benson, E., Engstrom, A., Sajosi, P., Briggs, A., and Bonthapally, V. (2017) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics, 20(1), pp. 8-18. (doi:10.1080/13696998.2016.1219358) (PMID:27472034)

Bousquet, J. et al. (2016) ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 6, 47. (doi:10.1186/s13601-016-0137-4) (PMID:28050247) (PMCID:PMC5203711)

Briggs, A. (2016) A view from the bridge: health economic evaluation - a value-based framework? Health Economics, 25(12), pp. 1499-1502. (doi:10.1002/hec.3448) (PMID:27870333)

Wilkinson, T. et al. (2016) The international decision support initiative reference case for economic evaluation: an aid to thought. Value in Health, 19(8), pp. 921-928. (doi:10.1016/j.jval.2016.04.015) (PMID:27987641)

Gumley, A. et al. (2016) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). Schizophrenia Research, (doi:10.1016/j.schres.2016.11.026) (PMID:27894822) (In Press)

Briggs, A. H., Parfrey, P. S., Khan, N., Tseng, S., Dehmel, B., Kubo, Y., Chertow, G. M., and Belozeroff, V. (2016) Analyzing health-related quality of life in the evolve trial: the joint impact of treatment and clinical events. Medical Decision Making, 36(8), pp. 965-972. (doi:10.1177/0272989x16638312) (PMID:26987347) (Early Online Publication)

Wildman, J., McMeekin, P., Grieve, E., and Briggs, A. (2016) Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. Social Science and Medicine, 169, pp. 141-148. (doi:10.1016/j.socscimed.2016.09.033) (PMID:27721138)

Bouttell, J., Lewsey, J., Geue, C., Antony, G., Briggs, A., McCartney, G., Hutchinson, S., Graham, L., and Heydtmann, M. (2016) The SCottish alcoholic liver disease evaluation: a population-level matched cohort study of hospital-based costs, 1991-2011. PLoS ONE, 11(10), e0162980. (doi:10.1371/journal.pone.0162980) (PMID:27783619)

Willett, K. et al. (2016) Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a randomized clinical trial. JAMA: Journal of the American Medical Association, 316(14), pp. 1455-1463. (doi:10.1001/jama.2016.14719) (PMID:27727383)

Williams, C., Lewsey, J. D., Briggs, A. H., and Mackay, D. F. (2016) Estimation of survival probabilities for use in cost-effectiveness analysis: a comparison of a multi-state modelling survival analysis approach with partitioned survival and Markov decision-analytic modelling. Medical Decision Making, (doi:10.1177/0272989X16670617) (PMID:27698003) (Early Online Publication)

Keene, D. J. et al. (2016) The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. Health Technology Assessment, 20(75), (doi:10.3310/hta20750) (PMID:27735787)

Städler, N., Shang, A., Bosch, F., Briggs, A., Goede, V., Berthier, A., Renaudin, C., and Leblond, V. (2016) A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia. Advances in Therapy, 33(10), pp. 1814-1830. (doi:10.1007/s12325-016-0398-2) (PMID:27535291)

Hoogendoorn, M. et al. (2016) Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine? Value in Health, 19(6), pp. 800-810. (doi:10.1016/j.jval.2016.04.002) (PMID:27712708)

Wolowacz, S. E., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A., and Norman, R. (2016) Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health, 19(6), pp. 704-719. (doi:10.1016/j.jval.2016.06.001) (PMID:27712695)

Tabberer, M., Gonzalez-McQuire, S., Muellerova, H., Briggs, A., Rutten-van Molken, M., Chambers, M., and Lomas, D. A. (2016) Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Medical Decision Making, (doi:10.1177/0272989X16662009) (PMID:27486218) (Early Online Publication)

Bousquet, J. et al. (2016) Scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016(6), 29. (doi:10.1186/s13601-016-0116-9) (PMID:27478588) (PMCID:PMC4966705)

Lawson, K., Briggs, A., Lewsey, J., Ford, I., Watt, G., Tunstall-Pedoe, H., Woodward, M., Ritchie, L., Kent, S., and Neilson, M. (2016) A cardiovascular disease policy model: part 2 – preparing for economic evaluation and to assess health inequalities. Open Heart, 3(1), e000140. (doi:10.1136/openhrt-2014-000140) (PMID:27335653) (PMCID:PMC4908904)

Lee, M. M.Y. et al. (2016) Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 3(1), e000371. (doi:10.1136/openhrt-2015-000371) (PMID:27110377) (PMCID:PMC4838768)

Boyd, K. A., Briggs, A. H., Bauld, L., Sinclair, L., and Tappin, D. (2016) Are financial incentives cost-effective to support smoking cessation during pregnancy? Addiction, 111(2), pp. 360-370. (doi:10.1111/add.13160) (PMID:26370095)

Briggs, A., and Nugent, R. (2016) Editorial. Health Economics, 25(S1), pp. 6-8. (doi:10.1002/hec.3321) (PMID:26804358)

Thiele, H. et al. (2016) Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 172, pp. 160-169. (doi:10.1016/j.ahj.2015.11.006) (PMID:26856228)

Becker, U., Briggs, A. H., Moreno, S. G., Ray, J. A., Ngo, P., and Samanta, K. (2016) Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy. Value in Health, 19(4), pp. 374-382. (doi:10.1016/j.jval.2015.12.018) (PMID:27325329)

Tremblay, G., Livings, C., Crowe, L., Kapetanakis, V., and Briggs, A. (2016) Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. ClinicoEconomics and Outcomes Research, 2016(8), pp. 323-333. (doi:10.2147/CEOR.S107498) (PMID:27418847) (PMCID:PMC4934460)

Williams, C., Lewsey, J. D., Briggs, A. H., and Mackay, D. F. (2016) Cost-effectiveness analysis in R using a multi-state modelling survival analysis framework: a tutorial. Medical Decision Making, (doi:10.1177/0272989X16651869) (PMID:27281337) (Early Online Publication)

Jahoda, A., Melville, C., Cooper, S.-A., Hastings, R., Briggs, A., Dagnan, D., Hatton, C., McConnachie, A., Williams, C., and Jones, R. P. (2015) BEAT-IT: a randomised controlled trial comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: summary of study protocol. Trials, 16, 595. (doi:10.1186/s13063-015-1103-5) (PMID:26714891) (PMCID:PMC4696180)

Belozeroff, V., Chertow, G. M., Graham, C. N., Dehmel, B., Parfrey, P. S., and Briggs, A. H. (2015) Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value in Health, 18(8), pp. 1079-1087. (doi:10.1016/j.jval.2015.08.007) (PMID:26686794)

Nam, J. et al. (2015) Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015(13), 19. (doi:10.1186/s12962-015-0045-9) (PMID:26578850) (PMCID:PMC4647286)

McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi:10.1016/j.jval.2015.09.887) (PMID:26532224)

Bousquet, J. et al. (2015) MACVIA-ARIA sentinel networK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy, 70(11), pp. 1372-1392. (doi:10.1111/all.12686) (PMID:26148220)

Reed, S. D. et al. (2015) Tools for economic analysis of patient management interventions in heart failure cost-effectiveness model: a web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. American Heart Journal, 170(5), pp. 951-960. (doi:10.1016/j.ahj.2015.08.015) (PMID:26542504)

Boyd, K. A., Jones, R. J., Paul, J., Birrell, F., Briggs, A. H., and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi:10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Lorgelly, P. K., Lorimer, K., Fenwick, E. A.L., Briggs, A. H., and Anand, P. (2015) Operationalising the capability approach as an outcome measure in public health: the development of the OCAP-18. Social Science and Medicine, 142, pp. 68-81. (doi:10.1016/j.socscimed.2015.08.002) (PMID:26291444)

Gumley, A. et al. (2015) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). Psychosis, pp. 1-13. (doi:10.1080/17522439.2015.1100669)

Old, O., Moayyedi, P., Love, S., Roberts, C., Hapeshi, J., Foy, C., Stokes, C., Briggs, A., Jankowski, J., and Barr, H. (2015) Barrett's oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. Journal of Medical Screening, 22(3), pp. 158-164. (doi:10.1177/0969141315575052) (PMID:25767103)

Wolowacz, S., Pearson, I., Shannon, P., Chubb, B., Gundgaard, J., Davies, M., and Briggs, A. (2015) Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabetic Medicine, 32(8), pp. 1023-1035. (doi:10.1111/dme.12663) (PMID:25484028)

Govan, L., Wu, O., Lindsay, R., and Briggs, A. (2015) How do diabetes models measure up? A review of diabetes economic models and ADA guidelines. Journal of Health Economics and Outcomes Research, 3(2), pp. 132-152.

Husereau, D., Drummond, M., Petrou, S., Greenberg, D., Mauskopf, J., Augustovski, F., Briggs, A. H., Moher, D., Loder, E., and Carswell, C. (2015) Reply to Roberts et al.: CHEERS is sufficient for reporting cost-benefit analysis, but may require further elaboration. PharmacoEconomics, 33(5), pp. 535-536. (doi:10.1007/s40273-015-0277-8) (PMID:25893576)

Stollenwerk, B., Lhachimi, S. K., Briggs, A., Fenwick, E., Caro, J. J., Siebert, U., Danner, M., and Gerber-Grote, A. (2015) Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Economics, 24(4), pp. 481-490. (doi:10.1002/hec.3041) (PMID:24590819)

Geue, C., Lorgelly, P., Lewsey, J., Hart, C., and Briggs, A. (2015) Hospital expenditure at the end-of-life: what are the impacts of health status and health risks? PLoS ONE, 10(3), e0119035. (doi:10.1371/journal.pone.0119035) (PMID:25746728) (PMCID:PMC4352086)

Layland, J. et al. (2015) Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 36(2), pp. 100-111. (doi:10.1093/eurheartj/ehu338) (PMID:25179764) (PMCID:PMC4291317)

Cook, J. A. et al. (2015) Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. Trials, 16(1), 12. (doi:10.1186/s13063-014-0526-8) (PMID:25928502) (PMCID:PMC4302137)

Devereux, G. et al. (2015) Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 16, 267. (doi:10.1186/s13063-015-0782-2) (PMID:26058585) (PMCID:PMC4465017)

Haines, P., Tremblay, G., and Briggs, A. (2015) A criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data. Journal of Health Economics and Outcomes Research, 2(2), pp. 147-160.

Lewsey, J. et al. (2015) Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 15(3), (doi:10.1186/s12883-014-0257-1) (PMID:25591718) (PMCID:PMC4320501)

Logue, J. et al. (2015) SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. BMJ Open, 5(5), e008106. (doi:10.1136/bmjopen-2015-008106) (PMID:26002692) (PMCID:PMC4442215)

Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi:10.1007/s00125-014-3383-9)

Geue, C., Briggs, A., Lewsey, J., and Lorgelly, P. (2014) Population ageing and healthcare expenditure projections: new evidence from a time to death approach. European Journal of Health Economics, 15(5), pp. 885-896. (doi:10.1007/s10198-013-0543-7)

Boyd, K.A., Briggs, A.H., Bauld, L., Sinclair, L., and Tappin, D. (2014) Are financial incentives cost-effective for smoking cessation amongst pregnant women? European Journal of Public Health, 24(S2), p. 146. (doi:10.1093/eurpub/cku162.090)

Bousquet, J. et al. (2014) Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 44(2), pp. 304-323. (doi:10.1183/09031936.00014614)

Hoogendoorn, M. et al. (2014) Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value in Health, 17(5), pp. 525-536. (doi:10.1016/j.jval.2014.03.1721)

Cook, J. A., Hislop, J. M., Altman, D. G., Briggs, A. H., Fayers, P. M., Norrie, J. D., Ramsay, C. R., Harvey, I. M., and Vale, L. D. (2014) Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice. Clinical Trials, 11(3), pp. 300-308. (doi:10.1177/1740774514521907) (PMID:24603006)

Boyd, K.A., Jones, R.J., Paul, J., Briggs, A., and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi:10.1002/bjs.9510)

Cooke, J. A. et al. (2014) Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. Health Technology Assessment, 18(28), v-vi, 1. (doi:10.3310/hta18280)

Levy, A. R., Briggs, A. H., Johnston, K., MacLean, J. R., Yuan, Y., L’Italien, G. J., Kalsekar, A., and Schnitzler, M. A. (2014) Projecting long-term graft and patient survival after transplantation. Value in Health, 17(2), pp. 254-260. (doi:10.1016/j.jval.2014.01.001)

Caro, J.J., Eddy, D. M., Kan, H., Kaltz, C., Patel, B., Eldessouki, R., and Briggs, A. H. (2014) Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value in Health, 17(2), pp. 174-182. (doi:10.1016/j.jval.2014.01.003)

Looker, H.C. et al. (2014) Risk stratification for diabetic eye screening: reply to Stratton I. M. and Aldington S. J. Diabetologia, 57(1), pp. 260-261. (doi:10.1007/s00125-013-3099-2)

Samyshkin, Y., Kotchie, R. W., Mörk, A.-C., Briggs, A. H., and Bateman, E. D. (2014) Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. European Journal of Health Economics, 15(1), pp. 69-82. (doi:10.1007/s10198-013-0456-5) (PMID:23392624) (PMCID:PMC3889819)

Campbell, J. D., McQueen, R. B., and Briggs, A. (2014) The “E” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Annals of the American Thoracic Society, 11(Sup 2), S105-S111. (doi:10.1513/AnnalsATS.201309-295RM)

Dundas, R., Ouédraogo, S., Bond, L., Briggs, A.H., Chalmers, J., Gray, R., Wood, R., and Leyland, A.H. (2014) Evaluation of Health in Pregnancy grants in Scotland: a protocol for a natural experiment. BMJ Open, 4(10), e006547. (doi:10.1136/bmjopen-2014-006547)

Hislop, J. et al. (2014) Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) Systematic Review. PLoS Medicine, 11(5), e1001645. (doi:10.1371/journal.pmed.1001645)

Lewsey, J.D. et al. (2014) A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. Heart, 101(3), pp. 201-208. (doi:10.1136/heartjnl-2014-305637)

Munge, K., and Briggs, A. H. (2014) The progressivity of health-care financing in Kenya. Health Policy and Planning, 29(7), pp. 912-920. (doi:10.1093/heapol/czt073)

Willett, K. et al. (2014) Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing close contact casting (CCC) to open surgical reduction and internal fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. BMC Musculoskeletal Disorders, 15, 79. (doi:10.1186/1471-2474-15-79) (PMID:24621174) (PMCID:PMC4234276)

Berry, C. et al. (2013) Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. American Heart Journal, 166(4), 662-668.e3. (doi:10.1016/j.ahj.2013.07.011)

Jaime Caro, J., Eddy, D.M., Hollingworth, W., Tsevat, J., McDonald, K.M., Wong, J.B., Briggs, A.H., Siebert, U., and Kuntz, K.M. (2013) ISPOR-SMDM task force’s recommendations for good modeling practices—reply to letter to the editor by Corro Ramos. Value in Health, 16(6), p. 1108. (doi:10.1016/j.jval.2013.06.016)

Looker, H.C. et al. (2013) Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia, 56(8), pp. 1716-1725. (doi:10.1007/s00125-013-2928-7)

Roberts, N.J., Lewsey, J.D., Gillies, M., Briggs, A.H., Belozeroff, V., Globe, D.R., Chiou, C.-F., Lin, S.-L., and Globe, G. (2013) Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: a retrospective cohort study from 1981-2009. Respiratory Medicine, 107(8), pp. 1172-1177. (doi:10.1016/j.rmed.2013.04.004)

Tigbe, W.W., Briggs, A.H., and Lean, M.E.J. (2013) A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. International Journal of Obesity, 37(8), pp. 1135-1139. (doi:10.1038/ijo.2012.186)

Garrison, L.P., Towse, A., Briggs, A., de Pouvourville, G., Grueger, J., Mohr, P.E., Severens, J.L., Siviero, P., and Sleeper, M. (2013) Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ispor good practices for performance-based risk-sharing arrangements task force. Value in Health, 16(5), pp. 703-719. (doi:10.1016/j.jval.2013.04.011)

Hemingway, H. et al. (2013) Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. British Medical Journal, 2013(346), e5595. (doi:10.1136/bmj.e5595)

Riley, R. D. et al. (2013) Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Medicine, 10(2), e1001380. (doi:10.1371/journal.pmed.1001380)

Murphy, A., Fenwick, E., Toff, W.D., Neilson, M.P., Berry, C., Uren, N., Oldroyd, K.G., and Briggs, A.H. (2013) Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. International Journal of Technology Assessment in Health Care, 29(01), pp. 12-19. (doi:10.1017/S0266462312000670)

Davies, C., Briggs, A., Lorgelly, P., Garellick, G., and Malchau, H. (2013) The 'hazards' of extrapolating survival curves. Medical Decision Making, 33(3), pp. 369-380. (doi:10.1177/0272989X12475091) (PMID:23457025)

Grutters, J.P.C., Sculpher, M., Briggs, A.H., Severens, J.L., Candel, M.J., Stahl, J.E., de Ruysscher, D., Boer, A., Ramaekers, B.L.T., and Joore, M.A. (2013) Acknowledging patient heterogeneity in economic evaluation. PharmacoEconomics, 31(2), pp. 111-123. (doi:10.1007/s40273-012-0015-4)

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., and Loder, E. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 16(2), pp. 231-250. (doi:10.1016/j.jval.2013.02.002)

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., and Loder, E. (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. British Medical Journal, 346(f1049), (doi:10.1136/bmj.f1049)

Lloyd, S.M. et al. (2013) Long-term effects of statin treatment in elderly people: Extended follow-up of the PROspective study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE, 8(9), e72642. (doi:10.1371/journal.pone.0072642)

Silveirinha de Oliveira, E., Aspinall, P., Briggs, A., Cummins, S., Leyland, A., Mitchell, R., Roe, J., and Ward Thompson, C. (2013) How effective is the Forestry Commission Scotland's woodland improvement programme--'Woods In and Around Towns' (WIAT)--at improving psychological well-being in deprived urban communities? A quasi-experimental study. BMJ Open, 3(8), e003648. (doi:10.1136/bmjopen-2013-003648)

Geue, C., Lewsey, J., Lorgelly, P., Govan, L., Hart, C., and Briggs, A. (2012) Spoilt for choice: implications of costing hospital episode statistics. Health Economics, 21(10), pp. 1201-1216. (doi:10.1002/hec.1785)

Briggs, A.H., Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J., and Paltiel, A.D. (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value in Health, 15(6), pp. 835-842. (doi:10.1016/j.jval.2012.04.014)

Caro, J.J., Briggs, A.H., Siebert, U., and Kuntz, K.M. (2012) modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value in Health, 15(6), pp. 796-803. (doi:10.1016/j.jval.2012.06.012)

Wu, O., Briggs, A., and MacIntyre, K. (2012) Mobile phone use for contacting emergency services in life-threatening circumstances. Journal of Emergency Medicine, 42(3), pp. 291-298. (doi:10.1016/j.jemermed.2011.02.022)

Briggs, A. (2012) The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Research in Medicine, 3(1), e25-e26. (doi:10.1016/j.ehrm.2012.01.001)

Briggs, A.H., Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J., and Paltiel, A.D. (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group - 6. Medical Decision Making, 32(5), pp. 722-732. (doi:10.1177/0272989X12458348)

Caro, J.J., Briggs, A.H., Siebert, U., and Kuntz, K.M. (2012) Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force - 1. Medical Decision Making, 32(5), pp. 667-677. (doi:10.1177/0272989X12454577)

Govan, L. et al. (2012) The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. Diabetologia, 55(9), pp. 2356-2360. (doi:10.1007/s00125-012-2601-6)

Roberts, N.J., Boyd, K., Briggs, A.H., Caress, A.L., and Partridge, M.R. (2012) Nurse led versus lay educators support for those with asthma in primary care: a costing study. BMC Pulmonary Medicine, 12(52), (doi:10.1186/1471-2466-12-52)

Tappin, D.M. et al. (2012) The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. Trials, 13(113), (doi:10.1186/1745-6215-13-113) (PMID:22818493) (PMCID:PMC3482147)

McLean, R.C., Briggs, A.H., Slack, R., Zamvar, V., Berg, G.A., El-Shafei, H., Oldroyd, K.G., and Pell, J.P. (2011) Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. European Journal of Cardio-Thoracic Surgery, 40(6), pp. 1508-1514. (doi:10.1016/j.ejcts.2011.01.088)

Boyd, K.A., Briggs, A.H., Fenwick, E., Norrie, J., and Stock, S. (2011) Power and sample size for cost-effectiveness analysis: fFN neonatal screening. Contemporary Clinical Trials, 32(6), pp. 893-901. (doi:10.1016/j.cct.2011.07.007)

Govan, L. et al. (2011) Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 34(9), pp. 1992-1997. (doi:10.2337/dc10-2099)

Macpherson, K.J. et al. (2011) Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 11(1), p. 38. (doi:10.1186/1471-2377-11-38)

Price, M.J., Welton, N.J., Briggs, A.H., and Ades, A.E. (2011) Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. Value in Health, 14(2), pp. 205-218. (doi:10.1016/j.jval.2010.08.001)

Starkie, H.J., Briggs, A.H., Chambers, M.G., and Jones, P. (2011) Predicting EQ-5D Values Using the SGRQ. Value in Health, 14(2), pp. 354-360. (doi:10.1016/j.jval.2010.09.011)

Bauld, L., Boyd, K. A., Briggs, A. H., Chesterman, J., Ferguson, J., Judge, K., and Hiscock, R. (2011) One-Year Outcomes and a Cost-Effectiveness Analysis for Smokers Accessing Group-Based and Pharmacy-Led Cessation Services. Nicotine and Tobacco Research, 13(2), pp. 135-145. (doi:10.1093/ntr/ntq222)

Barton, P., Andronis, L., Briggs, A., McPherson, K., and Capewell, S. (2011) Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal, 343, d4044. (doi:10.1136/bmj.d4044)

Bousquet, J. et al. (2011) How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. Allergy, 66(6), pp. 765-774. (doi:10.1111/j.1398-9995.2011.02590.x)

Boyd, K.A., Briggs, A., Paul, J., Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L., and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi:10.1186/1745-6215-12-S1-A41)

Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A., and Fenwick, E.L. (2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 14(1), pp. 15-23. (doi:10.1016/j.jval.2010.10.016)

Govan, L. et al. (2011) Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 54(8), pp. 2000-2008. (doi:10.1007/s00125-011-2176-7)

Boyd, K.A., Fenwick, E., and Briggs, A. (2010) Using an iterative approach to economic evaluation in the drug development process. Drug Development Research, 71(8), pp. 470-477. (doi:10.1002/ddr.20421)

Mihaylova, B., Briggs, A., O'Hagan, A., and Thompson, S.G. (2010) Review of statistical methods for analysing healthcare resources and costs. Health Economics, 20(8), pp. 897-916. (doi:10.1002/hec.1653)

Briggs, A.H., Glick, H.A., Lozano-Ortega, G., Spencer, M., Calverley, P.M.A., Jones, P.W., and Vestbo, J. (2010) Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal, 35(3), pp. 532-539. (doi:10.1183/09031936.00153108)

Briggs, A., Ritchie, K., Fenwick, E., Chalkidou, K., and Littlejohns, P. (2010) Access with evidence development in the UK past experience, current initiatives and future potential. PharmacoEconomics, 28(2), pp. 163-170. (doi:10.2165/11531410-000000000-00000)

Lorgelly, P.K. et al. (2010) An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 12(1), pp. 66-74. (doi:10.1093/eurjhf/hfp172)

Briggs, A.H. (2010) Transportability of comparative effectiveness and cost-effectiveness between countries. Value in Health, 13, S22-S25. (doi:10.1111/j.1524-4733.2010.00751.x)

Campbell, H.E., Gray, A.M., Harris, A.L., Briggs, A.H., and Taylor, M.A. (2010) Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. British Journal of Cancer, 103(6), pp. 776-786. (doi:10.1038/sj.bjc.6605863)

Crott, R., and Briggs, A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. European Journal of Health Economics, 11(4), pp. 427-434. (doi:10.1007/s10198-010-0233-7)

Dolan, G.P., Stone, D.H., and Briggs, A. (2010) A systematic review of continuous performance task research in children prenatally exposed to alcohol. Alcohol and Alcoholism, 45(1), pp. 30-38. (doi:10.1093/alcalc/agp062)

Hollingworth, W., Campbell, J.D., Kowalski, J., Ravelo, A., Girod, I., Briggs, A., and Sullivan, S.D. (2010) Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Quality of Life Research, 19(3), pp. 323-331. (doi:10.1007/s11136-010-9590-z)

Johnston, K.M., Levy, A.R., Lima, V.D., Hogg, R.S., Tyndall, M.W., Gustafson, P., Briggs, A.H., and Montaner, J.S. (2010) Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS, 24(12), pp. 1929-1935. (doi:10.1097/QAD.0b013e32833af85d)

Langhorne, P. et al. (2010) Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), pp. 1301-1305. (doi:10.1136/jnnp.2009.195131)

Lewsey, J. et al. (2010) Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 8, p. 23. (doi:10.1186/1741-7015-8-23)

Lorgelly, P.K., Lawson, K.D., Fenwick, E.A.L., and Briggs, A.H. (2010) Outcome Measurement in Economic Evaluations of Public Health Interventions: a Role for the Capability Approach? International Journal of Environmental Research and Public Health, 7(5), pp. 2274-2289. (doi:10.3390/ijerph7052274)

Levy, A., Harrigan, B., Johnston, K., and Briggs, A. (2009) Comparative effectiveness research through the looking glass. Medical Decision Making, 29(6), NP6-NP8. (doi:10.1177/0272989X09351590)

Lewsey, J. et al. (2009) Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2(5), pp. 475-483. (doi:10.1161/CIRCOUTCOMES.108.825968)

Jacobs-van der Bruggen, M. A. M., van Baal, P. H., Hoogenveen, R. T., Feenstra, T. L., Briggs, A. H., Lawson, K., Feskens, E. J. M., and Baan, C. A. (2009) Cost-effectiveness of lifestyle modification in diabetes patients. Diabetes Care, 32(8), pp. 1453-1458. (doi:10.2337/dc09-0363)

Wu, O., Levy, A.R., Briggs, A., Lewis, G., and Jardine, A. (2009) Acute rejection and chronic nephropathy: a systematic review of the literature. Transplantation, 87(9), pp. 1330-1339. (doi:10.1097/TP.0b013e3181a236e0)

Lewsey, J.D. et al. (2009) Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke, 40(4), pp. 1038-1043. (doi:10.1161/STROKEAHA.108.542787)

Mihaylova, B., Briggs, A., Hlatky, M., Armitage, J., Parish, S., Gray, A., and Collins, R. (2009) Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation: Cardiovascular Quality and Outcomes, 2(2), pp. 65-72. (doi:10.1161/CIRCOUTCOMES.108.808469)

Boyd, K.A., and Briggs, A.H. (2009) Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction, 104(2), pp. 317-325. (doi:10.1111/j.1360-0443.2008.02449.x)

Levy, A.R., Szabo, S., Briggs, A., Pleil, A., Davie, A., Zlateva, G., and Javitt, J. (2009) Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. Journal of Ophthalmology, 2009, 540431. (doi:10.1155/2009/540431) (PMID:20339464) (PMCID:PMC2836847)

Barton, G.R., Briggs, A.H., and Fenwick, E.A.L. (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value in Health, 11(5), pp. 886-897. (doi:10.1111/j.1524-4733.2008.00358.x)

Hirst, A., Dutton, S., Wu, O., Briggs, A., Edwards, C., Waldenmaier, L., Maresh, M., Nicholson, A., and McPherson, K. (2008) A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids: the HOPEFUL study. Health Technology Assessment, 12(5),

Briggs, A.H., Spencer, M., Wang, H., Mannino, D., and Sin, D.D. (2008) Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Archives of Internal Medicine, 168(1), pp. 71-79. (doi:10.1001/archinternmed.2007.37)

Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., and Mukherjee, J. (2008) Impact of schizophrenia and schizophrenia treatment related adverse events on quality of life: direct utility elicitation. Health and Quality of Life Outcomes, 6(105), pp. 1-9. (doi:10.1186/1477-7525-6-105)

Claxton, K., Briggs, A.H., Buxton, M.J., Culyer, A.J., McCabe, C., Walker, S., and Sculpher, M.J. (2008) Value based pricing for NHS drugs: an opportunity not to be missed? British Medical Journal, 336(7638), pp. 251-254. (doi:10.1136/bmj.39434.500185.25)

Eckerman, S., Briggs, A., and Willan, A.R. (2008) Health technology assessment in the cost-disutility plane. Medical Decision Making, 28(2), pp. 172-181. (doi:10.1177/0272989X07312474)

Hirst, A., Dutton, S., Wu, O., Briggs, A., Edwards, C., Waldenmaier, L., Maresh, M., Nicholson, A., and McPherson, K. (2008) The HOPEFUL Study: a multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation (UAE) for the treatment of symptomatic uterine fibroids. Health Technology Assessment, 123(5), pp. 1-248.

Levy, A.R., Kowdley, K., Iloeje, U.H., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N., and Briggs, A.H. (2008) The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health, 11(3), pp. 527-538. (doi:10.1111/j.1524-4733.2007.00297.x)

Starkie, H., Briggs, A.H., and Chamber, M.G. (2008) Pharmacoeconomics in COPD: lessons for the future. International Journal of COPD, 3(1), pp. 71-88.

Campbell, H., Briggs, A.H., Buxton, M., Kim, L., and Thompson, S. (2007) The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. Journal of Health Services Research and Policy, 12(1), pp. 11-17. (doi:10.1258/135581907779497594)

Briggs, A. et al. (2007) Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 93(9), pp. 1081-1086.

Culyer, A., McCabe, C., Briggs, A.H., Claxton, K., Buxton, M., Akehurst, R., Sculpher, M.J., and Brazier, J. (2007) Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 12(1), pp. 56-58.

Kim, L., Thompson, S., Briggs, A., Buxton, M., and Campbell, H. (2007) How cost-effective is screening for abdominal aortic aneurysms? Journal of Medical Screening, 14(1), pp. 46-52.

Luc, G., Ades, A., Sutton, A., Cooper, N., BriggS, A., and Caldwell, D. (2007) Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine, 26, pp. 3681-3699. (doi:10.1002/sim.2831)

Ossa, D.F., Briggs, A.H., McIntosh, E., Cowell, W., Littlewood, T., and Sculpher, M.J. (2007) Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. PharmacoEconomics, 25(3), pp. 223-237.

Mihaylova, B., Briggs, A.H., Armitage, J., Parish, S., Gray, A., and Collins, R. (2006) Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. British Medical Journal, 333(7579), p. 1145. (doi:10.1136/bmj.38993.731725.BE)

Briggs, A.H., Bousquet, J., Wallace, M., Busse, W.W., Clark, T.J.H., Pedersen, S.E., and Baternan, E.D. (2006) Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy, 61(5), pp. 531-536. (doi:10.1111/j.1398-9995.2006.01038.x)

Briggs, A.H., and Levy, A.R. (2006) Pharmacoeconomics and pharmacoepidemiology - Curious bedfellows or a match made in heaven? PharmacoEconomics, 24, pp. 1079-1086.

Briggs, A.H., Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D., and Burge, S. (2006) Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health, 9(4), pp. 227-235. (doi:10.1111/j.1524-4733.2006.00106.x)

Deckers, J., Goedhart, D., Boersma, E., Briggs, A., Bertrand, M., Ferrari, R., Remme, W., Fox, K., and imoons, M. (2006) Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal, 27, pp. 796-801. (doi:10.1093/eurheartj/ehi809)

Williams, C. et al. (2006) Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment, 10, 1-+.

Manca, A., Rice, N., Sculpher, M.J., and Briggs, A.H. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics, 14(5), pp. 471-485. (doi:10.1002/hec.914)

Claxton, K., Sculpher, M., McCabe, C., Briggs, A.H., Akehurst, R., Buxton, M., Brazier, J., and O'Hagan, T. (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics, 14(4), pp. 339-347. (doi:10.1002/hec.985)

Briggs, A.H. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2. (doi:10.1111/j.1524-4733.2005.08101.x)

Briggs, A.H., Nixon, R., Dixon, S., and Thompson, S. (2005) Parametric modelling of cost data: some simulation evidence. Health Economics, 14(4), pp. 421-428. (doi:10.1002/hec.941)

Briggs, A. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2.

Clarke, P., Gray, A., Briggs, A., Stevens, R., Matthews, D., and Holman, R. (2005) Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia, 48(5), pp. 868-877.

Gagnon, Y., Levy, A., Spencer, M., Hurley, J., Frost, F., Mapel, D., and Briggs, A. (2005) Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respiratory Medicine, 99(12), pp. 1534-1545.

Manca, A., Rice, N., Sculpher, M., and Briggs, A. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.[erratum appears in Health Econ. Health Economics, 14(5), pp. 471-485.

Mihaylova, B., Briggs, A., Armitage, J., Parish, S., Gary, A., and Collins, R. (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet, 365(9473), pp. 1779-1785.

O'Hagan, T. et al. (2005) Incorporation of uncertainty in health economic modelling studies. PharmacoEconomics, 23(6), pp. 529-536.

Ramsey, S. et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value in Health, 8(5), pp. 521-533.

Reed, S. et al. (2005) Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. American Heart Journal, 149(3), pp. 434-443.

Spencer, M.D., Briggs, A.H., Grossman, R.J., and Rance, L. (2005) Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. PharmacoEconomics, 23(6), pp. 619-637.

Clarke, P.M., Gray, A.M., Briggs, A., Farmer, A.J., Fenn, P.,, Stevenson, R.J., Matthews, D.R., Stratton, I.M., and Holman, R.R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47(10), pp. 1747-1759. (doi:10.1007/s00125-004-1527-z)

Briggs, A.H. (2004) Statistical approaches to handling uncertainty in health economic evaluation. Psychiatrist, 16(6), pp. 551-561.

Briggs, A. (2004) Statistical approaches to handling uncertainty in health economic evaluation. [29 refs]. European Journal of Gastroenterology and Hepatology, 16(6), pp. 551-561.

Briggs, A., Sculpher, M., Dawson, J., Fitzpatrick, R., Murray, D., and Malchau, H. (2004) The Use of Probabilistic Decision Models in Technology Assessment: The Case of Total Hip Replacement. Applied Health Economics and Health Policy, 3(2), pp. 78-79.

Clarke, P., Gray, A., Briggs, A., Farmer, A., Fenn, P., Stevens, R., Matthews, D., Stratton, I., and Holman, R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47, pp. 1747-1759. (doi:10.1007/s00125-004-1527-z)

Gagnon, Y., Levy, A., Iloeje, U., and Briggs, A. (2004) Treatment costs in Canada of health conditions resulting from chronic Hepatitis B infection. Journal of Clinical Gastroenterology, 38(Suppl), S179-S186.

Willan, A., Briggs, A., and Hoch, J. (2004) Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics, 13(5), pp. 461-475.

Clarke, P., Gray, A., Legood, R., Briggs, A., and Holman, R. (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine, 20(6), pp. 442-450. (doi:10.1046/j.1464-5491.2003.00972.x)

Reed, S.D., Dillingham, P.W., Briggs, A.H., Veestra, D.L., and Sullivan, S.D. (2003) A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. Medical Decision Making, 23(3), pp. 252-264. (doi:10.1177/0272989X03023003007)

Briggs, A., Ades, A., and Price, M. (2003) Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making, 23(4), pp. 341-350.

Briggs, A., Clark, T., Wolstenholme, J., and Clark, P. (2003) Missing ... presumed at random: cost analysis of incomplete data. Health Economics, 12(5), pp. 377-393.

Craig, D. et al. (2003) New BMJ policy on economic evaluations. Economic evaluations should be judged on economic merit. British Medical Journal, 326(7386), p. 445.

Hoch, J., Briggs, A., and Willan, A. (2003) Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics, 11(5), pp. 415-430.

Hope, A., and Briggs, A. (2003) Concerns regarding the ISPOR Code of Ethics for Researchers. Value in Health, 7(4), pp. 510-511.

Tytgat, G., Heading, R., Muller-Lissner, S., Kamm, M., Scholmerich, J., Berstad, A., Fried, M., Chaussade, S., Jewell, D., and Briggs, A. (2003) Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Alimentary Pharmacology and Therapeutics, 18(3), pp. 291-301. (doi:10.1046/j.1365-2036.2003.01679.x)

Briggs, A., Clark, T., Wolstenholme, J., and Clarke, P. (2002) Missing.... presumed at random: cost-analysis of incomplete data. Health Economics, 12(5), pp. 377-392. (doi:10.1002/hec.766)

O'Brien, B.J., and Briggs, A.H. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468. (doi:10.1191/0962280202sm304ra)

Briggs, A.H., O'Brien, B.J., and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401. (doi:10.1146/annurev.publhealth.23.100901.140534)

Blackhouse, G., Briggs, A., and O'Brien, B.J. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177. (doi:10.1177/02729890222063053)

Blackhouse, G., Briggs, A., and O'Brien, B. (2002) Estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22, pp. 170-174.

Blackhouse, G., Briggs, A., and O'Brien, B. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177.

Briggs, A.H., Goeree, R., Blackhouse, G., and O'Brien, B.J. (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308. (doi:10.1177/027298902400448867)

Briggs, A., Goeree, R., and O'Brien, B. (2002) Probabilistic analysis of models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308.

Briggs, A., O'Brien, B., and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401.

Goeree, R., O'Brien, B., Blackhouse, G., Marshall, J., Briggs, A., and Lad, R. (2002) Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value in Health, 5(4), pp. 312-328.

O'Brien, B., and Briggs, A. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468.

Price, M.J., and Briggs, A.H. (2002) Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics, 20(3), pp. 183-194.

Sendi, P.P., and Briggs, A.H. (2001) Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Economics, 10(7), pp. 675-680. (doi:10.1002/hec.639)

Briggs, A.H., and O'Brien, B.J. (2001) The death of cost-minimization analysis? Health Economics, 10(2), pp. 179-184. (doi:10.1002/hec.584)

Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.

Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.

Briggs, A., and O'Brien, B. (2001) The death of cost-minimization analysis?. [23 refs]. Health Economics, 10(2), pp. 179-184.

Briggs, A., and Tambour, M. (2001) The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions. Drug Information Journal, 35(4), pp. 1455-1468.

Delaney, B.C., Wilson, S.L., Roalfe, A., Briggs, A.H., and Hobbs, F.D.R. (2001) Empirical treatment or prompt endoscopy? - author's reply. Lancet, 357, p. 1366. (doi:10.1016/S0140-6736(00)04492-5)

Glick, H., and Briggs, A. (2001) Cost-effectiveness of health care interventions: a guide to quantifying stochastic uncertainty and presenting the result of cost-effectiveness analyses. Expert Reviews in Pharmacoeconomics and Outcomes Research, 1(1), pp. 25-36.

Levy, A., Briggs, A., Demers, C., and O'Brien, B. (2001) Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. American Heart Journal, 142(3), pp. 537-543.

Book Sections

Briggs, A. (2014) Statistical issues in economic evaluations. In: Culyer, A. J. (ed.) Encyclopedia of Health Economics. Elsevier, pp. 352-361. ISBN 9780123756787 (doi:10.1016/B978-0-12-375678-7.01418-8)

Boyd, K., and Briggs, A. (2013) Statistical issues with trial data and economic modeling for cost-effectiveness evaluation. In: Tang, W. and Tu, X. (eds.) Modern Clinical Trial Analysis. Series: Applied bioinformatics and biostatistics in cancer research. Springer-Verlag: New York, NY, USA, pp. 149-166. ISBN 9781461443216 (doi:10.1007/978-1-4614-4322-3_6)

Briggs, A., Starkie, H., and Wu, O. (2009) Health economics in asthma and COPD. In: Barnes, P.J., Drazen, J.M., Rennard, S.I. and Thomson, N.C. (eds.) Asthma and COPD. Academic Press/Elsevier: London, pp. 751-760. ISBN 9780123740014

Research Reports or Papers

Grieve, E., and Briggs, A. (2017) A Methodological Approach for Measuring the Impact of HTA. Technical Report. F1000Research.

Conference Proceedings

Paul, J., Briggs, A., Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A., and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.

This list was generated on Thu Mar 30 21:14:39 2017 BST.